Infiltración prostática por Leucemia/Linfoma de células T del adulto (HTLV-1+): reporte de caso
DOI:
https://doi.org/10.5281/zenodo.21839142Palabras clave:
Próstata, Linfoma de células T, Antígeno Prostático Específico, Virus Linfotrópico T Humano Tipo 1, Leucemia-Linfoma de células T del AdultoResumen
A diferencia de los frecuentes adenocarcinomas derivados del epitelio ductal, el compromiso prostático por linfoma o leucemia representa una variante inusual de neoplasia urológica. Estas afecciones pueden detectarse ante un tacto rectal anormal o un aumento del PSA sérico. El caso que se presenta es el de un hombre de 49 años, portador de HTLV-1 positivo, con síntomas del tracto urinario inferior (LUTS) y PSA persistentemente elevado, en quien se confirmó un linfoma de células T con compromiso prostático. El diagnóstico se sustentó en un perfil inmunohistoquímico intensamente positivo para CD4, CD5, CD25 y BCL2, y negativo para pancitoqueratina, CD20 y otros marcadores T/linfoides (CD7, CD8, CD10, CD30, ALK1 y EBER). Si bien excepcionales (<0,1% de las neoplasias prostáticas), los linfomas y leucemias con compromiso de próstata deben incluirse en el diagnóstico diferencial cuando el cuadro clínico o imagenológico es atípico para adenocarcinoma,
Descargas
Referencias
Coupland, S. (1877). Lymphoma (Lymphosarcoma) of the prostate, secondary nodules in the pancreas and the suprarenal capsule. Trans, Path. Soc, 28, 179–185.
Jacobi, M. (1937). Leukaemic infiltration of the prostate. J Urol, 38, 494–499.
Bostwick DG, Mann RB. Malignant lymphomas involving the prostate: a study of 13 cases. Cancer. 1985;56(12):2932-2938.
Phillips SMA, Ferry DR, Lee SJ. Carcinoma of the prostate mimicking lymphoma. Br J Urol. 1994;73(5):590-1. Disponible en: https://doi.org/10.1111/j.1365-2141.1991.tb08051.x
Floyd-Aristizábal D, Barreiro García CA, Arias-Valderrama O, Proaño Millán C, Silva Perez NM, Rosales Martinez JD, et al. Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center. Ther Adv Hematol. 2025; 16:20406207251316178. Disponible en: https://doi.org/10.1177/20406207251316178
Rodríguez-Zúñiga MJM, Cortez-Franco F, Qujiano-Gomero E. Leucemia/linfoma de células T del adulto. Revisión de la literatura científica. Actas Dermosifiliogr. 2018;109(5):399-407. Disponible en: https://doi.org/10.1016/j.ad.2017.08.014
Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83(4):732-8. Disponible en: https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4%3C732::AID-CNCR15%3E3.0.CO;2-T
Zein TA, Huben R, Lane W, Pontes JE, Englander LS. Secondary tumors of the prostate. J Urol. 1985;133(4):615-6. Disponible en: https://doi.org/10.1016/S0022-5347(17)49111-7
Johnson TR, Barber DB, Teichman JM, Able AC. T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report. J Spinal Cord Med. 1996;19(4):258-60. Disponible en: https://doi.org/10.1080/10790268.1996.11719443
Yamada S, Nabeshima A, Nagata Y, Tasaki T, Noguchi H, Kitada S, et al. Pleomorphic carcinoma of the breast associated with cyst formation: a unique surgical case focusing on cytological and immunohistochemical findings. Diagn Pathol. 2013;8:75. Disponible en: https://doi.org/10.1186/1746-1596-8-75
Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-7. Disponible en: https://doi.org/10.1182/blood-2015-03-632489
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37(8):677-87. Disponible en: https://doi.org/10.1200/JCO.18.00501
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-64. Disponible en: https://doi.org/10.1200/JCO.2007.11.9958
Inxight Drugs (NCATS). Ranimustine (MCNU). Accessed 2025. https://drugs.ncats.io/drug/8Y014W8QCW
European Medicines Agency (EMA). Eldisine (vindesine): supply shortage notice. Updated Feb 5, 2025.
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104(6):1624-30. Disponible en: https://doi.org/10.1182/blood-2003-12-4428
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-801. Disponible en: https://doi.org/10.1002/cncr.20668
PDQ Adult Treatment Editorial Board. Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37437079/
National Cancer Institute. PDQ® Adult Acute Lymphoblastic Leukemia Treatment—Health Professional Version [Internet]. Bethesda (MD): National Cancer Institute; updated 2025. Disponible en: https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq
Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097-103. Disponible en: https://doi.org/10.3324/haematol.2017.167742
Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101(1):e27-e29. Disponible en: https://doi.org/10.3324/haematol.2015.131151
Pishko AM, Levine LD, Cines DB. Thrombocytopenia in pregnancy: Diagnosis and approach to management. Blood Rev. 2020; 40:100638. Disponible en: https://doi.org/10.1016/j.blre.2019.100638
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426-33. Disponible en: https://doi.org/10.1200/JCO.2016.67.8250
Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5(20):4156-66. Disponible en: https://doi.org/10.1182/bloodadvances.2021004932
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Paloma Belén Aquez Chirino, Felipe Coloma Ortiz, Martin Guillermo Zuñiga Soria, Valentina Maria Consuelo Diaz Tapia (Autor/a)
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
